Trial Profile

Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vincristine (Primary) ; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Imatinib; Mesna; Methotrexate; Methylprednisolone sodium succinate; Pegfilgrastim; Rituximab; Ruxolitinib
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

31 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended as addition of new primary end points as Overall Survival and Complete Response Duration.
12 Nov 2020 Status changed from active, no longer recruiting to completed.
01 Jul 2020 Results (n=31) published in the American Journal of Hematology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com